NCT01575548 2026-03-18
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
71 trialsNCT01684397 2026-02-27
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT07087158 2025-07-28
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT03592472 2025-04-13
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT01767636 2025-03-03
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Phase 2 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT05949424 2023-11-29
OPTI-DOSE
University Medical Center Groningen
Phase 4 Unknown
NCT03200717 2023-08-21
IO-PAZ
Novartis
Phase 2 Completed
NCT05816642 2023-04-18
Application Circulating Tumor DNA Dynamic Monitoring in Clinical Treatment of Metastatic Renal Cell Carcinoma
RenJi Hospital
Phase NA Unknown
NCT01157091 2022-06-08
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03334409 2022-03-31
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Terminated
NCT01566747 2021-12-23
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Phase 2 Completed
NCT01472081 2021-12-02
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
Phase 1 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02959554 2021-09-08
NIVOSWITCH
AIO-Studien-gGmbH
Phase 2 Terminated
NCT02960906 2021-04-26
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Phase 2 Completed
NCT02555748 2021-01-12
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT01235962 2020-11-23
PROTECT
Novartis
Phase 3 Completed
NCT01649778 2020-07-15
PRINCIPAL
Novartis
Completed
NCT04462445 2020-07-10
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01221506 2020-03-26
Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC)
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT02406521 2020-03-04
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02014636 2020-03-03
Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)
Novartis
Phase 1 Completed
NCT01392352 2020-02-13
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Terminated
NCT03571438 2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA Unknown
NCT02795819 2019-10-24
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
Virginia Commonwealth University
Phase 1 Terminated
NCT03379012 2019-10-22
FARETES
Kidney Cancer Research Bureau
Phase 2 Completed
NCT01184326 2019-10-02
Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03519542 2019-09-18
SOGANG
Spanish Oncology Genito-Urinary Group
Completed
NCT02729194 2019-06-10
Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT00387205 2019-03-06
Study To Assess Long Term Safety Of Pazopanib
Novartis
Phase 1 Completed
NCT01832259 2018-12-12
A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection
University of Utah
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT01158521 2018-09-12
Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01385228 2018-06-06
Pazopanib, Docetaxel, Prednisone Prostate
Duke University
Phase 1 Completed
NCT02282579 2018-04-26
SPAZO
Spanish Oncology Genito-Urinary Group
Completed
NCT01361113 2018-04-25
Neoadjuvant Pazopanib in Renal Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01012362 2017-12-28
Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00158782 2017-11-17
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00363194 2017-11-17
A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients
GlaxoSmithKline
Phase 1 Completed
NCT00478725 2017-11-17
Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034
GlaxoSmithKline
Phase 1 Completed
NCT00861029 2017-11-14
VEG111485: A QTc Study of Pazopanib
GlaxoSmithKline
Phase 1 Completed
NCT00401583 2017-11-13
A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes
GlaxoSmithKline
Phase 1 Completed
NCT00516672 2017-11-13
Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors
GlaxoSmithKline
Phase 1 Completed